Altered fractionation radiotherapy combined with concurrent low-dose or high-dose cisplatin in head and neck cancer: A systematic review of literature and meta-analysis

Improving patient outcomes, as the ultimate goal in oncology, greatly depends on concentrated efforts to promote public health programs, overcome challenges in diagnosis and disease management, and expand health care availability. In squamous cell carcinoma of the head and neck (SCCHN), the Surveillance, Epidemiology, and End Results (SEER) database revealed a substantial enhancement of the 5-year overall survival rate from 54.7% in 1990s to 65.9% in 2000s, particularly in patients with tongue (including base of tongue) and tonsil cancers, in whom the proportion of prognostically favourable human papillomavirus (HPV)-positive cases has been on the rise [1 –3].
Source: Oral Oncology - Category: Cancer & Oncology Authors: Tags: Review Source Type: research